Navidea Biopharmaceuticals Posts Lymphoseek® NDA Update to Company Website
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents, today posted on its website an update to the status of the Lymphoseek NDA review. The web access to the statement can be found on the Navidea Investor page at: http://phx.corporate-ir.net/phoenix.zhtml?c=68527&p=irol-nda.
Brent Larson, Sr. VP & CFO
Source: Navidea Biopharmaceuticals, Inc.
Released September 24, 2012